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Abstract
Background: Use of high daily doses of benzodiazepines is generally contraindicated for seniors.
While both patient and physician factors may influence the use of high daily doses, previous
research on the effect of patient factors has been extremely limited. The objectives of this study
were to determine the one year prevalence of use of high daily doses of benzodiazepines, and
examine physician and patient correlates of such use among Quebec community-dwelling seniors.
Methods: Patient information for 1423 community-dwelling Quebec seniors who participated in
the Canadian Study of Health and Aging was linked to provincial health insurance administrative
data bases containing detailed information on prescriptions received and prescribers.
Results:  The standardized one year period prevalence of use of high daily doses of
benzodiazepines was 7.9%. Use of high daily doses was more frequent among younger seniors and
those who had reported anxiety during the previous year. Patients without cognitive impairment
were more likely to receive high dose prescriptions from general practitioners, while those with
cognitive impairment were more likely to receive high dose prescriptions from specialists.
Conclusion: High dose prescribing appears to be related to both patient and physician factors.
Background
While there continues to be concern regarding the use of
benzodiazepines with seniors [1], most experts agree that
these drugs can be relatively effective and safe when pre-
scribed and taken in an appropriate manner [2]. Dose is
an important characteristic in determining the appropri-
ateness of a benzodiazepine prescription. We examined
the prevalence and correlates of the use of high daily
does of benzodiazepines among a group of seniors in
Quebec.
The use of high daily doses of benzodiazepines by seniors
is associated with a number of adverse outcomes includ-
ing hip fracture [3], and motor vehicle accidents [4,5], as
well as accidental falls, accidental poisonings, hospitali-
zations for depression and other psychiatric events and
attempted and completed suicides [6]. There is evidence
that dosage may be a more important risk for femoral
fracture than benzodiazepine half-life [3,7], and may be
especially problematic with oxidative benzodiazepines
[8]. Due to the widespread use of benzodiazepines
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among seniors, even a relatively low prevalence of high
dose use may have a substantial impact on public health.
Research to investigate the prevalence and correlates of
the use of high daily doses is therefore extremely impor-
tant.
To date, three studies of the prevalence and correlates of
high dose benzodiazepine prescribing to Canadian sen-
iors have been reported. In British Columbia, examina-
tion of the provincial drug plan data bases revealed that
four percent of British Columbia seniors received pre-
scriptions for daily doses of 20 mg diazepam equivalent
or more during 1990 [9]. The average daily dose of ben-
zodiazepines received by Nova Scotia seniors between
1993 and 1996, according to the provincial administra-
tive drug data base, was found to be generally higher
than recommended geriatric doses. However, extreme
variation in the daily doses measured led the authors to
question the validity of the results [10]. When benzodi-
azepine hypnotic prescriptions were examined by select-
ed pharmacists in Ontario and Quebec, approximately
one-third of triazolam and oxazepam prescriptions and
two-thirds of flurazepam prescriptions were considered
high dose [11]. Lack of a recognized standard in these
studies defining a high daily dose, as well as limitations
in the information contained in provincial data bases,
have made it difficult to compare the prevalence of high
dose prescribing over time and across provinces.
A limited number of patient and prescriber characteris-
tics have been examined as potential correlates of use of
high daily doses, including patient age and physician
gender, specialty status and prescribing tendencies.
Younger seniors were more likely to use high daily doses
[11,12]. Male physicians were somewhat more likely to
prescribe high doses than female physicians. General
practitioners were more likely to write high dose pre-
scriptions as were physicians who were frequent pre-
scribers of benzodiazepines [9].
Interpretation of the findings regarding physician fac-
tors associated with high daily dose prescribing are diffi-
cult since, in these studies, there was no consideration of
patient characteristics which might inform dosing. For
example, the use of a higher than recommended daily
dose may be required for an individual with severe anxi-
ety, one who has developed tolerance for the drug with
long-term use [13], or a heavier individual [14]. Lower
doses are recommended for individuals with cognitive
impairment [15,16] or those in poor health [17]. Such
characteristics may confound or alter relationships be-
tween physician characteristics and prescribing behav-
iour. A clearer picture of physician characteristics
associated with high dose prescribing, and any patient
characteristics which affect prescribing decisions, is im-
perative for the development of programs to lessen high
dose prescribing.
The objectives of this study were to determine the preva-
lence of use of high daily doses among Quebec seniors
using a standard definition of high daily doses and to
evaluate the association between high daily dose pre-
scribing and physician characteristics while also consid-
ering patient factors. This study was carried out using
patient data from the first wave of the Canadian Study of
Health and Aging (CSHA1) [18]. The CSHA1 was a major
nation-wide study carried out primarily to determine the
prevalence of dementia in Canada. For the present study,
data from the CSHA1 were linked to prescribing data
from the Quebec provincial health insurance drug data
base.
Methods
Subjects
Quebec community-dwelling seniors who participated in
the screening phase of the first wave of the Canadian
Study of Health and Aging (CSHA1) [18] formed the
study population. Eligible individuals were those 65
years of age and older on October 1, 1990, who lived in
Chicoutimi, Montreal, Quebec City and Sherbrooke, or
the rural areas surrounding these cities. Exclusion crite-
ria included lack of fluency in English or French, pres-
ence of a life-threatening illness and residence in a
nursing home, long-stay hospital or other collective
dwelling (e.g. a convent). Subjects were selected from
provincial health insurance plan records using a strati-
fied random sample. Of those 2549 eligible Quebec sub-
jects who could be contacted, 1778 (69.8%) were
screened for dementia between February 1, 1991 and
May 1, 1992 using the Modified Mini-Mental Status ex-
amination (3MS) [19].
Data linkage
During the CSHA1 screening interviews Quebec subjects
were asked to provide their health insurance (RAMQ)
numbers. Information from CSHA1 and RAMQ was
linked using subjects' health insurance numbers. RAMQ
guidelines specified that information could not be re-
leased for subjects who possessed a unique profile of
characteristics which could allow identification of those
subjects following data linkage. It was therefore neces-
sary to group CHSA1 subjects into characteristic-defined
subgroups containing multiple members. A file contain-
ing these data was then forwarded to the RAMQ Statisti-
cal Services Department who carried out the linkage and
replaced each subject's individual RAMQ number with a
scrambled identifying code.BMC Geriatrics 2001, 1:4 http://www.biomedcentral.com/1471-2318/1/4
Measurements
Subjects were categorized according to whether they had
filled one of more prescriptions for benzodiazepines dur-
ing the 365 days following screening and then further
categorized as to whether or not any of their benzodi-
azepine prescriptions were for high daily doses. A pre-
scription was defined as a high daily dose if the
prescribed dosage was higher than the Defined Daily
Dose (DDD) for that particular benzodiazepine [20]. The
DDD is the unit of daily drug consumption set by the
World Health Organization (WHO) to allow estimation
regional per capita consumption of drugs regions when
only sales data are available. In this study the DDDs for
benzodiazepines were used to differentiate a standard
dose of the drug and a high dose. The DDD's for study
benzodiazepines are compared with the manufacturers'
prescribing guidelines in use just prior to the study peri-
od [21] and the diazepam equivalents [22] in Table 1.
Patient gender, age (66–69, 70–74, 75–79, 80+ years),
subjective anxiety (whether the patient reported "prob-
lems with his/her nerves" during the year prior to
screening), and score on the 3MS (< 78 versus 78+, max-
imum score in cognitively intact = 100) were extracted
from CSHA1 data. Using all prescriptions filled during
the year prior to CSHA1 screening, a Chronic Disease
Score (CDS) [23] was calculated for each patient. The
CDS provides a measure of health status by considering
the number and severity of chronic diseases for which a
patient is receiving pharmacotherapy. A score of 4 or
more represents relatively poor health. Higher scores on
the CDS have been associated with increased risk of hos-
pitalization and death [23,24]. In addition, use of benzo-
diazepines during the previous year was ascertained by
examining the RAMQ data for the presence of a benzodi-
azepine prescription during the 365 days prior to CSHA1
screening.
The most frequent prescriber of high or low dose benzo-
diazepine prescriptions was identified for each subject.
The prescriber's year of graduation (1980+, 1970–79,
1960–69, 1959 or earlier), gender and whether the phy-
sician was a generalist (i.e. general practitioner or family
physician) or a specialist were derived from RAMQ
records.
Data analysis
The one year period prevalence of use of high daily doses
was determined and standardized by age and gender to
the 1991 Quebec population.
Among subjects who used benzodiazepines during the
year following screening, the odds ratio of use of high
daily doses associated with each patient and prescriber
characteristic was calculated. Backward logistic regres-
sion was used to produce a model of main effects. Then
patient factors which potentially modified the relation-
ships between physician characteristics and use of high
daily doses were identified, added to and tested in the
model of main effects. Significant main effects and inter-
action terms were retained in the final model. All calcu-
lations were performed using SAS version 6.04 software
[25].
Ethics
Ethics approval for the present study was granted by the
Research Ethics Committee of the Sir Mortimer B. Davis-
Jewish General Hospital, November 3, 1995.
Table 1: Defined Daily Doses
Benzodiazepine DDD (mg) Diazepam equivalent 
(mg)(21)
CPS (22) maximum 
adult daily dose (mg)
Maximum geriatric dose – 
(Jenike) [26]
Maximum geriatric dose 
(Beers et al.) [27]
alprazolam 1 10 3 0.5 NG
bromazepam 10 16.67 30 NG NG
chlordiazepox-
ide
30 15 40 30 NR
diazepam 10 10 40 10 NR
flurazepam 30 5 30 NG NR
lorazepam 2.5 12.5 4 4 NG
nitrazepam 5 2.5 10 NG NG
oxazepam 50 16.67 120 30 30.00
temazepam 20 3.33 30 30 NG
triazolam 0.25 5 0.5 0.5 0.25
Note. DDD = Defined Daily Dose; CPS = Compendium of Pharmaceutical Specialties; NG=not given; NR=not recommendedBMC Geriatrics 2001, 1:4 http://www.biomedcentral.com/1471-2318/1/4
Results
Of the 1778 Quebec CSHA1 community-dwelling sub-
jects who received a screening interview, 1460 provided
a RAMQ number. Valid RAMQ numbers and sufficient
data on patient characteristics were available for 1423
subjects who thus formed the study sample. When these
1423 subjects were compared with the 355 subjects not
included in the data linkage, subjects included in the
linkage were more likely to be female, and more likely to
have screened negative for cognitive impairment. How-
ever, linked and non-linked subjects did not differ by age
at screening or anxiety (data not shown).
Of the 1423 subjects whose CSHA1 data were linked to
RAMQ records, 607 (42.7%) filled at least one prescrip-
tion for a benzodiazepine during the 12 months following
CSHA1 screening (standardized one year prevalence:
41.3%).
Of the 5638 benzodiazepine prescriptions, 787 (14.0%)
were for high daily doses. The proportion of high dose
prescriptions varied by type of benzodiazepine (Figure
1). Of the 1423 study subjects, 108 (7.6%) filled at least
one high daily dose prescription (standardized one year
prevalence: 7.9%).
The above analysis considered single drugs only. One
hundred and twenty-three subjects received more than
one type of benzodiazepine on a given day. In a post hoc
analysis, all distinct benzodiazepines received by a given
subject on a particular day were identified and the pro-
portion of the DDD of each was summed. Using this ap-
proach, 132 (9.3%) subjects were identified as high dose
users (standardized one year prevalence: 9.6%).
When unadjusted associations between use of high daily
doses and patient and physician factors were considered
for the 607 benzodiazepine users (Table 2), use of high
daily doses was more common among patients who had
reported anxiety and those who had previously used ben-
zodiazepines.
The final model predicting use of high daily doses includ-
ed patient age, anxiety and cognitive status and physi-
cian specialty status with an interaction between the
latter two factors (Table 3). Specifically the model indi-
cates that patients reporting anxiety and patients 66–74
years of age are more likely to receive high daily doses.
Specialists are less likely than general practitioners to
prescribe high doses when the patient does not have cog-
nitive impairment, but more likely to prescribe them
when the patient does have cognitive impairment.
Discussion
The one year prevalence of use of high daily doses found
in this study was 7.9%. A lower prevalence of use of high
doses (i.e. 4%) was found in the only comparable study of
British Columbia seniors [4]. However, in the British Co-
lumbia study, the one year prevalence of any use of ben-
zodiazepines was 23.4%, compared with 41.3% in the
Figure 1
Benzodiazepine prescriptions by doseBMC Geriatrics 2001, 1:4 http://www.biomedcentral.com/1471-2318/1/4
present study. Thus, the proportion of high dose use
among benzodiazepine users in British Columbia was
17% compared to 19% among the Quebec seniors in this
study. While the overall prevalence of use of high doses
was greater among Quebec seniors, the proportion of
high dose use among benzodiazepine users was similar
in the two provinces.
Results of this study seem to indicate that physicians
tended to avoid high daily dose prescriptions for patients
over 74 years of age, and were more likely to prescribe
high daily doses if the patient had chronic anxiety. Con-
trary to previous reports [4,7], we did not find a statisti-
cally significant relationship between high daily dose
prescribing and male physician gender or older age, as
reflected in year of graduation. However, relationships
were in the same direction as those reported previously.
While earlier studies demonstrated that specialists are
less likely to prescribe high daily doses than generalists
[4], we found that this may be true only with cognitively
intact patients. This study provides evidence that gener-
alists may be more likely than specialists to prescribe
high daily doses to seniors without cognitive problems,
but less likely than specialists to prescribe high daily dos-
es to those with cognitive impairment.
The limitations of this study included potential problems
due to cross-sectional methodology, use of the patient as
the unit of analysis, and use data on drug dispensing as a
proxy measure of drug use. Since both use of high daily
doses and patient and physician characteristics were
measured at the same time, it is impossible to make any
kind of statement of causality. For example, patients
with cognitive impairment who required high daily doses
Table 2: Unadjusted odds ratios for patient and prescriber characteristics and use of high daily doses
High daily dose Less than high daily dose
n (%) n (%) Odds ratio 95% CI
Prescriber Gender female 11 (10.2) 68 (13.6) 1 Reference
male 97 (89.8) 431 (86.4) 1.39 0.71–2.73
Year of graduation 1980+ 15 (13.9) 80 (16.0) 1 Reference
1970–79 40 (37.0) 211 (42.3) 1.01 0.53–1.93
1960–69 28 (25.9) 107 (21.4) 1.4 0.70–2.79
pre 1960 25 (23.1) 101 (20.2) 1.32 0.65–2.67
Specialist no 93 (18.6) 408 (81.4) 1 Reference
yes 15 (14.2) 91 (85.8) 0.72 0.40–1.31
Patient Gender female 70 (64.8) 357 (71.5) 1 Reference
male 38 (31.5) 142 (28.5) 1.37 0.88–2.12
Age 66–69 22 (20.4) 83 (16.6) 1 Reference
70–74 34 (23.6) 110 (22.0) 1.17 0.64–2.14
75–79 27 (31.5) 143 (28.7) 0.71 0.38–1.33
80+ 25 (23.1) 163 (32.7) 0.58 0.31–1.09
Anxiety no 62 (57.4) 353 (70.7) 1 Reference
yes 46 (42.8) 146 (29.3) 1.79 1.17–2.75
3MS > 78 82 (75.9) 361 (72.3) 1 Reference
< 78 26 (24.1) 138 (27.7) 0.83 0.51–1.34
CDS < 4 92 (85.2) 417 (83.6) 1 Reference
> 4 16 (14.8) 82 (16.4) 0.88 0.50–1.58
previous use no 6 (5.6) 65 (13.0) 1 Reference
yes 102 (94.4) 434 (87.0) 2.55 1.07–6.04
Table 3: Final model predicting use of high daily doses of 
benzodiazepines
Variable Parameter estimate Standard error P-value
Intercept -1.2676 0.1889
Anxiety (yes) 0.5874 0.2219 0.008
Age (75+ years) -0.5651 0.2195 0.01
3MS (< 78) -0.3952 0.2757 0.1518
Specialist (yes) -0.7598 0.3643 0.037
3MS* Specialist 1.7736 0.7013 0.0114BMC Geriatrics 2001, 1:4 http://www.biomedcentral.com/1471-2318/1/4
may have been more likely to present to specialists than
to general practitioners. Since analysis was carried out at
the patient level, selected prescribers may not be repre-
sentative of high dose prescribers in general. As well,
where physicians prescribed to two or more patients, sig-
nificance of associations may been overestimated. It
must also be noted that administrative data bases, such
as the one used, contain information on prescriptions as
filled. Patients may consume more or less of these medi-
cations over a shorter or more prolonged period of time.
While the RAMQ data base does contain a variable for
dosage which was used in the determination of dose in
this study, patients could have taken the drugs in a way
other than was prescribed.
Another potential limitation of the study is the use of the
DDD as an indicator of high dose prescribing. The DDD
was constructed to allow for an estimation of per capita
consumption of specific drugs based on aggregate
records such as sales data [15]. It was therefore originally
conceived of as a technical measure, not a clinical one.
However, the fact that it is both an internationally recog-
nized measure and one that allows for dosage compari-
sons between drug categories, makes it an excellent
choice if one wishes to compare prevalence of use at var-
ious dosage level over time and across regions. Clinically,
use of more than three-quarters of the DDD has been
found to be associated with increase risk of hip fracture
among benzodiazepine users 55 years of age and older
[1].
Finally, it must also be noted that this data reflects ben-
zodiazepine use among Quebec seniors during a one pe-
riod sometime between 1991 and 1993, the actual time
period dependent upon time of enrollment into the
CSHA1. Given increasing reports of the risks associated
with benzodiazepine use in the elderly, as well as cam-
paigns designed to optimize prescribing, one could ex-
pect that high dose prescribing is on the wane. However,
analysis of benzodiazepine prescriptions to seniors dur-
ing 1997 indicate that the proportion of high dose pre-
scriptions remains virtually unchanged (Monette, Grad,
Tamblyn, Jacques, LeCruguel & Avorn, manuscript in
preparation.).
While the use of high daily doses of benzodiazepines is
generally contraindicated for seniors, this study provides
evidence that such use is relatively common among the
elderly in Quebec. Those at highest risk for such use were
younger seniors and those who had reported anxiety
during the previous year. As well, this study indicates
that the relationship between physician specialty status
and high dose prescribing is more complex than previ-
ously believed, and may be associated with patient cogni-
tive impairment, with those patients suffering from
cognitive impairment less likely to receive high daily dos-
es from generalists.
There are implications of these results for basic and con-
tinuing medical education. First, since we found no asso-
ciation between year of graduation and high dose
prescribing, it is reasonable to assume that it is worth-
while to further emphasize the importance of keeping
dosage low for older patients. As well, our finding that
specialists may be more likely to write high dose pre-
scriptions in some situations warrants further investiga-
tion. There may be confounding factors for the finding
that these physicians prescribed higher doses for cogni-
tively impaired patients (e.g. more severe sleep prob-
lems), or it may be important to target this area of their
practice for continuing education.
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